Alexander Still, a celebrated former defensive end for the University of Kentucky and the Kansas City Chiefs, has shifted his focus from football glory to raising awareness about ATTR amyloidosis. Diagnosed in September 2023, this rare condition occurs when abnormal proteins accumulate in organs, impairing their function. Despite being fit and maintaining a healthy lifestyle, Still discovered he had atrial fibrillation during an NFL Players Association medical evaluation. Subsequent tests confirmed amyloidosis, a disease often challenging to diagnose, particularly affecting men and individuals of African descent. Since his diagnosis, Still has passionately campaigned to educate others, leveraging his platform as a Hall of Famer and UK alumnus.
The Journey of Alexander Still: From Football Stardom to Health Advocacy
In the vibrant autumn of 2023, amidst the golden hues of changing leaves, Alexander Still's life took an unexpected turn when he was diagnosed with ATTR amyloidosis. This hereditary condition primarily affects vital organs like the heart and kidneys, often manifesting through seemingly unrelated symptoms such as carpal tunnel syndrome and irregular heartbeats. Hailing from Camden, New Jersey, Still initially attributed his health issues to years of physical strain endured on the football field. However, thorough examinations at St. Luke’s Mid America Heart Institute revealed otherwise.
Still, now 69, embraced this revelation not with despair but determination. He embarked on a mission to inform and assist others battling similar challenges. His brother James "Sparky" Still's journey through a heart transplant due to the same ailment underscored the importance of early detection. With a growing family—eleven children and soon-to-be twenty-six grandchildren—Still prioritizes educating them about potential risks. Beyond personal concerns, he advocates vigilance within the African American community, where genetic predispositions heighten susceptibility.
At the UK Gill Heart & Vascular Institute, specialists like Dr. Sonu Abraham lead efforts in diagnosing and treating various forms of amyloidosis. They emphasize the significance of timely intervention, utilizing advanced methods including PET scans and genetic testing. Although no definitive cure exists, modern therapies offer hope in managing symptoms and slowing disease progression.
From Lexington, Kentucky, to nationwide platforms, Still continues championing awareness for this under-recognized condition. His story resonates deeply, inspiring countless individuals to seek knowledge and proactive healthcare measures.
As a journalist observing Still's transformation from athlete to advocate, one cannot help but admire his resilience and commitment. His journey highlights the critical need for increased understanding and resources regarding rare diseases. It serves as a poignant reminder that even legends face vulnerabilities beyond their control, yet they can channel these experiences into meaningful change. Through Still's unwavering dedication, we witness how personal trials can transform into opportunities for widespread education and support.